Eli Lilly is trading 3.13% down at $1,265.80, amid pressure on healthcare shares and broader risk-off sentiment; no clear company-specific negative announcement surfaced.
- The $5 billion Virginia manufacturing project announced October 22 was positive news, not an evident explanation for the decline.
- Quest Diagnostics disclosed a cyberattack, while geopolitical tensions and higher oil prices weighed on markets.
- Eli Lilly rose 2.83% in the prior session, making profit-taking a possible additional factor, though not a confirmed cause.